These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
394 related articles for article (PubMed ID: 518012)
1. Clotting, activated partial thromboplastin and coagulation times in monitoring heparin therapy. Kurec AS; Morris MW; Davey FR Ann Clin Lab Sci; 1979; 9(6):494-500. PubMed ID: 518012 [TBL] [Abstract][Full Text] [Related]
2. [Monitoring heparin therapy by thrombin time and activated partial thromboplastin time--a comparison]. Lang M; Fey MF; Furlan M; Beck EA Schweiz Med Wochenschr; 1986 Nov; 116(48):1681-4. PubMed ID: 3798064 [TBL] [Abstract][Full Text] [Related]
3. Clinical safety and cost of heparin titration using bedside activated clotting time. Thomason T; Riegel B; Jessen D; Smith SC; Gocka I; Rich M Am J Crit Care; 1993 Jan; 2(1):81-7. PubMed ID: 8353584 [TBL] [Abstract][Full Text] [Related]
4. Activated partial thromboplastin time and activated coagulation time in monitoring heparinized cats. Greene CE; Meriwether E Am J Vet Res; 1982 Aug; 43(8):1473-7. PubMed ID: 7103231 [TBL] [Abstract][Full Text] [Related]
5. [Measurement of activated whole blood coagulation as a control parameter for heparin dosage in hemodialysis]. Kraatz G; Lopot F Z Urol Nephrol; 1984 Aug; 77(8):465-71. PubMed ID: 6495895 [TBL] [Abstract][Full Text] [Related]
6. In vitro effects of aprotinin on activated clotting time measured with different activators. Wang JS; Lin CY; Hung WT; Thisted RA; Karp RB J Thorac Cardiovasc Surg; 1992 Oct; 104(4):1135-40. PubMed ID: 1383640 [TBL] [Abstract][Full Text] [Related]
7. Activated partial thromboplastin time is a better trending tool in pediatric extracorporeal membrane oxygenation. Maul TM; Wolff EL; Kuch BA; Rosendorff A; Morell VO; Wearden PD Pediatr Crit Care Med; 2012 Nov; 13(6):e363-71. PubMed ID: 22940857 [TBL] [Abstract][Full Text] [Related]
8. [Monitoring of heparin therapy with activated recalcification time]. Lutze G; Schlote A; Urbahn H Z Gesamte Inn Med; 1981 Feb; 36(4):102-6. PubMed ID: 7222858 [TBL] [Abstract][Full Text] [Related]
9. Research review: use of activated clotting time to monitor heparin therapy in coronary patients. Noureddine SN Am J Crit Care; 1995 Jul; 4(4):272-7; quiz 278-9. PubMed ID: 7663590 [TBL] [Abstract][Full Text] [Related]
10. Monitoring heparin therapy using activated partial thromboplastin time--results of a multicenter trial establishing the therapeutic range for SILIMAT, a reagent with high sensitivity to heparin. Toulon P; Boutière B; Horellou MH; Trzeciak MC; Samama MM Thromb Haemost; 1998 Jul; 80(1):104-8. PubMed ID: 9684794 [TBL] [Abstract][Full Text] [Related]
11. Heparin monitoring during coronary intervention: activated clotting time versus activated partial thromboplastin time. Nath FC; Muller DW; Rosenschein U; Ellis SG; Topol EJ Can J Cardiol; 1993 Nov; 9(9):797-801. PubMed ID: 8281479 [TBL] [Abstract][Full Text] [Related]
12. [Comparative multicenter study of a rabbit high-sensitivity thromboplastin and a recombinant thromboplastin with synthetic phospholipids]. Martínez-Brotóns F; Borrell M; Fontcuberta J; Batlle J; López F; Páramo JA; Ribera C; Rocha E; Vicente V; Zuazu I Sangre (Barc); 1994 Aug; 39(4):245-51. PubMed ID: 7985052 [TBL] [Abstract][Full Text] [Related]
13. Clinical evaluation of a new one-stage clotting assay for heparin and low molecular weight heparins. Harenberg J J Mal Vasc; 1987; 12 Suppl B():68-70. PubMed ID: 2834495 [TBL] [Abstract][Full Text] [Related]
14. Heparin dosing and monitoring for cardiopulmonary bypass. A comparison of techniques with measurement of subclinical plasma coagulation. Gravlee GP; Haddon WS; Rothberger HK; Mills SA; Rogers AT; Bean VE; Buss DH; Prough DS; Cordell AR J Thorac Cardiovasc Surg; 1990 Mar; 99(3):518-27. PubMed ID: 2308370 [TBL] [Abstract][Full Text] [Related]
15. [Laboratory controls of heparin therapy with thrombin time, partial thromboplastin time and activated recalcification time]. Lutze G; Presser HJ; Urbahn H Z Gesamte Inn Med; 1989 Apr; 44(8):235-40. PubMed ID: 2662657 [TBL] [Abstract][Full Text] [Related]
16. Monitoring activated clotting time for combined heparin and aprotinin application: in vivo evaluation of a new aprotinin-insensitive test using Sonoclot. Ganter MT; Monn A; Tavakoli R; Genoni M; Klaghofer R; Furrer L; Honegger H; Hofer CK Eur J Cardiothorac Surg; 2006 Aug; 30(2):278-84. PubMed ID: 16828293 [TBL] [Abstract][Full Text] [Related]
17. Activated clotting time differential is a superior method of monitoring anticoagulation following coronary angioplasty. Pitney MR; Kelly SA; Allan RM; Giles RW; McCredie M; Walsh WF Cathet Cardiovasc Diagn; 1996 Feb; 37(2):145-50. PubMed ID: 8808069 [TBL] [Abstract][Full Text] [Related]
18. Heparin monitoring in the coronary care unit after percutaneous transluminal coronary angioplasty. Varah N; Smith J; Baugh RF Heart Lung; 1990 May; 19(3):265-70. PubMed ID: 2341265 [TBL] [Abstract][Full Text] [Related]
19. Elevated activated partial thromboplastin time does not correlate with heparin rebound following cardiac surgery. Taneja R; Marwaha G; Sinha P; Quantz M; Stitt L; Gao R; Subramanian S; Schaus M; Keeney M; Chin-Yee I; Murkin J Can J Anaesth; 2009 Jul; 56(7):489-96. PubMed ID: 19408066 [TBL] [Abstract][Full Text] [Related]
20. Anti-factor Xa assay is a superior correlate of heparin dose than activated partial thromboplastin time or activated clotting time in pediatric extracorporeal membrane oxygenation*. Liveris A; Bello RA; Friedmann P; Duffy MA; Manwani D; Killinger JS; Rodriquez D; Weinstein S Pediatr Crit Care Med; 2014 Feb; 15(2):e72-9. PubMed ID: 24335992 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]